Top Banner
Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health
31

Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Dec 18, 2015

Download

Documents

Dwain Murphy
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Gilead -Topics in Human Pathophysiology

Fall 2009 Drug Safety and Public Health

Page 2: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Respiratory system and Disease

• Respiratory System structures– Airways– Respiratory interface– Gas transport– Lungs and ventilation

• Selected Respiratory Disorders

Page 3: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Unlabeled Figure 10.1

Page 4: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Figure 10.1

Page 5: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Respiratory Interface

• Alveolar wall• Capillary wall• Surfactant• Gas Exchange occurs by diffusion

Page 6: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Figure 10.8

Page 7: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Gas Transport

• Oxygen

• Carbon dioxide

Page 8: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Page 9: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Figure 10.7

Page 10: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Page 11: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Page 12: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Respiratory Disorders

• H1N1• Asthma• Cystic fibrosis• Pulmonary aspergillosis• Pneumonia

Page 13: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

H1N1• Cause

– Influenza A virus• Symptoms

– Fever– Sore throat– Cough– Body aches– Headache– Chills– Fatigue– Vomiting and diarrhea

Page 14: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

H1N1

Page 15: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

H1N1

• Susceptible populations• Antivirals for influenza – Tamiflu (oseltamivir),

Relenza (zanamivir), peramivir• Complications

– Pneumonia and respiratory failure– Bronchitis– Ear infections– Sinus infections

Page 16: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Asthma

Page 17: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Cystic fibrosis

• Inherited disorder causing a defect in a cell membrane Cl- channel

• Causes thick sticky mucus buildup in airways and ducts of pancreas, etc.

• Shortens lifespan because of pneumonia, malnutrition, etc.

Page 18: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Page 19: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Pulmonary aspergillosis

• Fungal lung infection• Common with AIDs patients and cystic fibrosis

patients• Treated with Ambisome (amphoterocin B),

one of several antifungals, alters fungal cell permeability

Page 20: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Pulmonary Aspergillosisfrom an AIDS patient during autopsy

http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijid/vol6n1/aspergillosis.xml

Page 21: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Pneumonia

• Fluid buildup in lung alveoli• Thickens respiratory interface, interrupting

diffusion of gases• Caused by a wide variety of microorganisms

including aspergillus and pneumocystis fungi, influenza virus (Tamiflu), cytomegalovirus (Vistide)

Page 22: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Pneumonia

Page 23: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Tests for Lung Function

• Chest X-ray (CXR)• Pulmonary function tests• Sputum cultures• Pulse oximetry• Arterial Blood Gases (ABGs)

Page 24: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Pneumonia X-ray

http://www.med-ed.virginia.edu/courses/rad/cxr/pathology3chest.html

Page 25: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Figure 22.16a

Pulmonary Function Tests

Page 26: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Figure 22.16a

FEV1

Should be at least 80% of

VC

FEV1

Should be at least 80% of

VC

(VC)

Page 27: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Sputum Culture

•Patient donates a sputum sample•It is cultured with various media to determine causative agent of lung infection

Page 28: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Pulse Oximetry

•Measures arterial hemoglobin oxygen saturation•Normal is > 95%•Indicator of effectiveness of respiratory interface and gas diffusion

Page 29: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.

Arterial Blood Gases

• pH• PCO2

• PO2

• O2 Saturation

• HCO3-

Page 30: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Page 31: Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.